Skip to Main Content


Dextromethorphan is a common antitussive agent found in many over-the-counter (OTC) cough and cold preparations. Dextromethorphan is often found in combination products containing antihistamines, decongestants, ethanol, or acetaminophen. Common combination products containing dextromethorphan include Coricidin HBP Cough & Cold Tablets, Robitussin DM, and NyQuil Nighttime Cold Medicine. Dextromethorphan is well tolerated at therapeutic doses, and serious toxicity rarely occurs, even with moderate-to-high doses. However, major toxicity and death have been reported, caused either by dextromethorphan as a sole agent or more commonly by coingestants, drug–drug interactions, or genetic polymorphism. Intentional abuse, especially among adolescents and young adults, has been a continuing problem owing to the hallucinogenic potential at high doses. Common slang terms include "triple C," "CCC," "skittles," "robo," "DXM," and "dex." "Crystal Dex" and "DXemon Juice" refer to dextromethorphan extracted from the other ingredients in OTC cold medications using simple home acid–base extraction techniques.


Although dextromethorphan is structurally related to opioids (its active metabolite is the d-isomer of levorphanol) and it has antitussive activity approximately equal to that of codeine, it has no apparent activity at mu or kappa receptors and does not produce a typical opioid syndrome in overdose.

  1. Dextromethorphan is metabolized in the liver by the cytochrome P450 isoenzyme CYP2D6 to dextrorphan. Both dextromethorphan and dextrorphan antagonize N-methyl-D-aspartate (NMDA) glutamate receptors, although dextrorphan is more potent and primarily responsible for the psychoactive effects of high-dose dextromethorphan. Genetic polymorphism of CYP2D6 may explain the variable clinical responses reported; extensive metabolizers are more likely to experience the "desirable" psychoactive effects with recreational use.

  2. Dextromethorphan and dextrorphan inhibit reuptake of serotonin and may lead to serotonin syndrome, especially in patients taking agents that increase serotonin levels, such as selective serotonin reuptake inhibitors (Antidepressants, General (Noncyclic)) and monoamine oxidase inhibitors. Serotoninergic effects, as well as NMDA glutamate receptor inhibition, may explain the acute and chronic abuse potential of dextromethorphan.

  3. Dextromethorphan hydrobromide can cause bromide poisoning.

  4. Many of the combination preparations contain acetaminophen, and overdose or abuse may result in hepatotoxicity.

  5. Pharmacokinetics. Dextromethorphan is well absorbed orally, and effects are often apparent within 15–30 minutes (peak, 2–2.5 hours). The volume of distribution is approximately 5–6 L/kg. The rate of metabolism is dependent on CYP2D6 polymorphism. Dextromethorphan has a plasma half-life of about 3–4 hours in extensive metabolizers versus a half-life exceeding 24 hours in slow metabolizers (about 10% of the population). In addition, dextromethorphan competitively inhibits CYP2D6-mediated metabolism of other drugs, leading to many potential drug interactions (see also Table II–66).


Establishing a clear correlation between dose and clinical effects is problematic, given wide patient variability, genetic polymorphism, and the fact that most of the scientific literature is comprised of self-reported poisonings involving combination products lacking laboratory confirmation. Moderate symptoms usually occur when the amount of dextromethorphan ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.